LSL Pharma Group Inc. (TSXV:LSL)
Canada · Delayed Price · Currency is CAD 0.3200
-0.0100 (-3.03%)
At close: Aug 28, 2026
LSL Pharma Group Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 41.83 | 28.74 | 17.75 | 10.03 | 8.21 | 8.77 | |
Revenue Growth | 80.01% | 61.96% | 76.98% | 22.08% | -6.35% | -12.70% |
Cost of Revenue | 36.66 | 21.92 | 12.4 | 8.38 | 10.39 | 6.89 |
Gross Profit | 5.17 | 6.82 | 5.35 | 1.65 | -2.17 | 1.88 |
Selling, General & Admin | 8.99 | 7.23 | 4.52 | 3.64 | 3.92 | 2.59 |
Research & Development | - | - | - | - | 0.67 | - |
Operating Expenses | 9.44 | 7.41 | 4.94 | 5.76 | 4.59 | 2.59 |
Operating Income | -4.26 | -0.59 | 0.41 | -4.12 | -6.76 | -0.71 |
Interest Expense | -3.52 | -2.64 | -1.75 | -1.57 | -1.39 | -1.71 |
Other Non Operating Income (Expenses) | -0.24 | -0.27 | -0.16 | -0.24 | -0.15 | - |
EBT Excluding Unusual Items | -8.02 | -3.5 | -1.5 | -5.92 | -8.29 | -2.41 |
Merger & Restructuring Charges | - | - | - | -2.55 | -0.43 | - |
Other Unusual Items | 0.62 | 0.62 | 4.86 | - | 0.66 | 0.78 |
Pretax Income | -7.4 | -2.89 | 3.37 | -8.47 | -8.06 | -1.63 |
Income Tax Expense | -0.07 | -0.07 | 0.05 | - | - | 0.15 |
Net Income | -7.34 | -2.82 | 3.32 | -8.47 | -8.06 | -1.78 |
Net Income to Common | -7.34 | -2.82 | 3.32 | -8.47 | -8.06 | -1.78 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 123 | 118 | 105 | 80 | 66 | 59 |
Shares Outstanding (Diluted) | 123 | 118 | 105 | 80 | 66 | 59 |
Shares Change | 6.62% | 11.54% | 31.18% | 20.94% | 11.78% | 8.34% |
EPS (Basic) | -0.06 | -0.02 | 0.03 | -0.11 | -0.12 | -0.03 |
EPS (Diluted) | -0.06 | -0.02 | 0.03 | -0.11 | -0.12 | -0.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -7.71 | -4.46 | -3.25 | -7.73 | -4.16 | -2 |
Free Cash Flow Per Share | -0.06 | -0.04 | -0.03 | -0.10 | -0.06 | -0.03 |
Gross Margin | 12.37% | 23.74% | 30.13% | 16.40% | -26.44% | 21.47% |
Operating Margin | -10.19% | -2.05% | 2.29% | -41.05% | -82.26% | -8.07% |
Profit Margin | -17.54% | -9.81% | 18.69% | -84.48% | -98.15% | -20.26% |
Free Cash Flow Margin | -18.44% | -15.53% | -18.31% | -77.04% | -50.66% | -22.80% |
EBITDA | -1.61 | 1.35 | 1.71 | -3.21 | -5.97 | 0.1 |
EBITDA Margin | -3.86% | 4.69% | 9.61% | -32.03% | -72.67% | 1.17% |
D&A For EBITDA | 2.65 | 1.94 | 1.3 | 0.9 | 0.79 | 0.81 |
EBIT | -4.26 | -0.59 | 0.41 | -4.12 | -6.76 | -0.71 |
EBIT Margin | -10.19% | -2.05% | 2.29% | -41.05% | -82.26% | -8.07% |
Effective Tax Rate | - | - | 1.49% | - | - | - |
Revenue as Reported | 41.83 | 28.74 | 17.75 | 10.03 | - | - |